Neil Palmisiano

Clinical trials

• Hydrochloroquinine & Decitabine With Venetoclax in AML

  Principal investigator · Not yet recruiting · Phase 1

  Rutgers, The State University of New Jersey

  2026–2028
• Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

  Principal investigator · Active not recruiting · Phase 1, Phase 2

  ECOG-ACRIN Cancer Research Group

  2018–2028
• Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  Site PI · Recruiting · Phase 1

  National Cancer Institute (NCI)

  2025–2028
• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2027